Ligand Pharmaceuticals IncorporatedLGNDNASDAQ
Loading
Operating Cash Flow Growth Under PressureDecelerating
Percentile Rank14
Studio
Year-over-Year Change

Year-over-year operating cash flow growth rate

Percentile
P14
Within normal range
vs 5Y Ago
-0.2x
Contraction
Streak
1 yr
Consecutive declineDecelerating
PeriodValue
2025-49.14%
202495.75%
2023-64.04%
202274.94%
202144.36%
2020286.07%
2019-115.12%
2018107.40%
201748.52%
201650.98%